Ali Mehdi, MD, MEd, is a board-certified nephrologist at Cleveland Clinic, where he also serves as assistant professor of medicine at the Lerner College of Medicine at Case Western Reserve University.

Ali Mehdi, MD, MEd

IgA nephropathy (IgAN) is no longer considered the benign disease it was once thought to be, with a growing share of patients now expected to eventually need renal replacement therapy.

HCPLive: IgA nephropathy care has changed dramatically in a relatively short period of time over the last few decades. What do you think has been the biggest paradigm shift in how clinicians should think about this disease?

Mehdi: I think the biggest thing that we've learned over the past few years is that IgA nephropathy is not the benign disease that we all unfortunately learned back in medical school and as nephrology fellows. We now realize that a big percentage of patients, even those who present with a seemingly indolent disease, will end up requiring renal replacement therapy at some point down the line. In a disease like IgA, the problem is that this could be decades down the line, but when you think of a disease that really starts at age 30 or 40, decades down the line is still a young adult, basically. So I think that's been the biggest realization about IgA, and that clearly made its way into the updated KDIGO guidelines for how we should be managing IgA nephropathy. It has already transformed how we approach, how we diagnose, how we risk stratify, and how we treat those patients.

HCPLive: IgAN is a heterogeneous disease, with patients experiencing different rates of progression and treatment responses. How should clinicians account for that variability when making treatment decisions?

Mehdi: We are still learning how to risk stratify our patients. IgA nephropathy is a heterogeneous disease. We have patients who present with fast, progressive kidney disease where they lose kidney function pretty rapidly over a few years, and we have patients who have hematuria and proteinuria with an indolent progression toward the need for renal replacement therapy down the line. We do have some ways to monitor these patients and risk stratify based on clinical parameters like proteinuria and estimated GFR, and then pathologic parameters that we get from a kidney biopsy, and that helps us establish the risk of progression toward end-stage kidney disease in the foreseeable future. That is not a perfect way to do it, and we are learning more from clinical trials about how to better identify which patient would benefit from what. That is an evolving chapter that's being written, and the heterogeneity doesn't help, but there's a lot of data hopefully coming over the next few years.

HCPLive: What is one change you hope to see in IgA nephropathy care over the next few years?

Mehdi: I think the biggest change I would like to see is being better able to phenotype patients to realize who would benefit from what treatment when. I think that would help us drastically, as opposed to relying on biomarkers of disease, biomarkers of the damage that's already been set, meaning estimated GFR slope and proteinuria. I'd like to be able to better phenotype my patients based on disease parameters that would tell me that this patient is high risk and would benefit from treatment X or Y, or would not benefit from treatment X or Y. I think that is bound to happen over the next 5 to 10 years, and it will dramatically shift the way we treat and manage our patients.

Kidney Disease: Improving Global Outcomes (KDIGO) IgAN/IgAV Work Group. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). 

Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. 

Articles

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd